Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased ...
Earnings and revenues beat the Zacks Consensus Estimate. Quarterly adjusted earnings of $1.61 per share beat the Zacks Consensus Estimate by 15.8% and increased 20.2% on a year-over-year basis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback